HRS-8427

HRS-8427 is an investigational antibiotic under development by Jiangsu Hengrui Medicine for the treatment of complicated urinary tract infections (including acute pyelonephritis), lung infections, and other gram-negative bacterial infections. It is administered intravenously. The drug is described as a cefiderocol derivative, suggesting it belongs to the siderophore cephalosporin class of antibiotics, which are designed to overcome resistance in gram-negative bacteria by utilizing bacterial iron transport systems for cell entry. As of early 2025, HRS-8427 has reached Phase III clinical trials for complicated urinary tract infection and pyelonephritis and Phase I trials for pulmonary infection[1][4][6][7]. The precise mechanism of action has not been publicly disclosed but is likely similar to other cefiderocol derivatives that inhibit bacterial cell wall synthesis.